Results 131 to 140 of about 81,174 (219)

Liver microsomal protein content and activity in patients with hepatocellular carcinoma and cirrhosis: implications for the <i>in vivo</i> prediction of individual hepatic clearance. [PDF]

J Gastrointest Oncol
Zhou J, Gao N, Tian X, Fang Y, Gao J, Wen Q, Cui MZ, Zhang YF, Li SF, Jia LJ, Qiao HL.   +10 more
europepmc   +1 more source

Metabolite‐Based Network Pharmacology, Molecular Docking, and Dynamics Simulations to Preliminarily Verify Treating Diabetic Encephalopathy Effect of Kuwanon G

Food Science &Nutrition, Volume 13, Issue 6, June 2025.
This study investigates the neuroprotective effects of Kuwanon G (KWG) against diabetic encephalopathy (DE) by characterizing its metabolic profile and therapeutic mechanisms. Using UHPLC‐Q‐TOF‐MS, network pharmacology, molecular docking, and dynamics simulations, 56 metabolites were identified, with nine showing high intestinal absorption and ...
Yuqian Zhang, Siying Zhang, Haiying Niu, Weiwei Xie, Yuxin Tan, Deqiang Li, Yiran Jin   +6 more
wiley   +1 more source

Acyl-CoA: lysophosphatidylcholine acyltransferase from diatom P. Tricornutum efficiently remodels phosphatidylcholine containing polyunsaturated fatty acids. [PDF]

Sci Rep
Jasieniecka-Gazarkiewicz K, Połońska A, Gong Y, Banaś A.   +3 more
europepmc   +1 more source

Clinical Assessment of the Drug–Drug Interaction Potential of Omaveloxolone in Healthy Adult Participants

The Journal of Clinical Pharmacology, Volume 65, Issue 6, Page 715-730, June 2025.
Abstract Omaveloxolone is approved in the United States and the European Union for the treatment of patients with Friedreich ataxia aged ≥16 years. It is mainly metabolized by cytochrome P450 (CYP) 3A4 in vitro. Two drug–drug interaction studies (NCT04008186 and NCT05909644) were performed to evaluate (1) the effect of drug‐metabolizing enzymes (DMEs ...
Hamim Zahir, Masako Murai, Lucy Wu, Michelle Valentine, Scott Hynes   +4 more
wiley   +1 more source

Species Differences in the Biotransformation of Aflatoxin B1: Primary Determinants of Relative Carcinogenic Potency in Different Animal Species. [PDF]

Toxins (Basel)
Eaton DL, Williams DE, Coulombe RA.
europepmc   +1 more source

Resveratrol: Molecular Mechanisms, Health Benefits, and Potential Adverse Effects

MedComm, Volume 6, Issue 6, June 2025.
As a polyphenol substance with important potential, resveratrol has important potential in degenerative diseases, cardiovascular diseases, cancer, neurological diseases, etc. However, it is still necessary to pay attention to its bioavailability and potential adverse effects.
Zhuo‐qun Ren, Sheng‐yuan Zheng, Zhengcheng Sun, Yan Luo, Yu‐tong Wang, Ping Yi, Yu‐sheng Li, Cheng Huang, Wen‐feng Xiao   +8 more
wiley   +1 more source

The In Vitro Pharmacokinetics of Medicinal Plants: A Review. [PDF]

Pharmaceuticals (Basel)
Chaves de Jesus P, Rego Rodrigues Silva DM, Macedo Moura PH, Gopalsamy RG, Dias Silva EE, Dos Santos Barreto M, Santana Santos R, Santos Martins AY, de Freitas Almeida AG, Santana Corrêa AK, Alves da Mota Santana L, Hariharan G, Gibara Guimarães A, Pinto Borges L.   +13 more
europepmc   +1 more source

The Influence of CYP2B6, GSTP1, and SLCO1B1 Star Allele‐Predicted Phenotypes and CBR1 Genetic Variants on Effectiveness Outcomes in Patients With Hepatocellular Carcinoma Receiving Doxorubicin via Transarterial Chemoembolization

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT We investigated the influence of CYP2B6, GSTP1, and SLCO1B1 star allele‐predicted phenotypes and CBR1 variants on clinical outcomes in patients with HCC receiving DOX via TACE. A prospective cohort of patients with HCC underwent DOX therapy via TACE.
Sireen Abdul Rahim Shilbayeh, Omnia A. Abd El‐Baset, Mohammad A. Alshabeeb, Abdalrhman Hamdan Alanizi, Naglaa F. Khedr, Rehab H. Werida   +5 more
wiley   +1 more source

Vitamin K preserves gamma-glutamyl carboxylase activity against carbamylations in uremia: Implications for vascular calcification and adjunct therapies. [PDF]

Acta Physiol (Oxf)
Kaesler N, Kaushik S, Frisch J, Ziegler S, Grommes J, Gombert A, Roma LP, Kuppe C, Jankowski J, Floege J, de la Puente-Secades S, Kramann R, Jankowski V.   +12 more
europepmc   +1 more source

The Effects of Different Administration Regimens of Berberine Hydrochloride on the Pharmacokinetics of Sirolimus in Rats

Pharmacology Research &Perspectives, Volume 13, Issue 3, June 2025.
ABSTRACT Sirolimus is a third‐generation immunosuppressant with multiple efficacies, including antifungal, antitumor, and immunosuppressive properties. We conducted a pharmacokinetic study to determine the effect of berberine hydrochloride (BBR) on the pharmacokinetics of sirolimus in rats.
Yuanxia Yang, Yue Zhang, Yingdong Qu, Liwan Cui   +3 more
wiley   +1 more source